Business Context and Reporting Period
MIMEDX GROUP, INC. is a development-stage enterprise focused on musculoskeletal products, including soft-tissue reconstructive products, fixation devices, and spinal products. The company operates in Destin, Florida, with laboratory facilities in Tampa, Florida, and a subsidiary, SpineMedica, in Marietta, Georgia. This Form 10-Q covers the quarterly period ended December 31, 2008, and the nine-month period ended December 31, 2008. The company has generated no operating revenue since its inception in November 2006.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2008 | Nine Months Ended Dec 31, 2008 | Balance Sheet (Dec 31, 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,309,055) | $(9,047,287) | N/A |
| Loss Attributable to Common Shareholders | $(3,044,055) | $(11,206,110) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $864,768 |
| Total Assets | N/A | N/A | $8,633,518 |
| Total Liabilities | N/A | N/A | $1,190,689 |
| Stockholders' Equity | N/A | N/A | $4,206,579 |
| Net Cash Used in Operating Activities | N/A | $(7,223,232) | N/A |
Note: The company reported no revenue. Margins are not applicable due to zero revenue. The company has no long-term debt listed on the balance sheet, but has significant contractual obligations.
Material Changes vs. Prior Period
- Operating Expenses: Research and development (R&D) expenses increased significantly to $886,270 for the three months ended Dec 31, 2008, from $563,094 in the prior year period. For the nine months, R&D rose to $3,065,625 from $1,221,101. This increase is attributed to expanded staff (26 R&D personnel vs. 15 in 2007) and higher external consultant fees.
- General and Administrative (G&A): G&A expenses decreased to $1,428,488 for the three months ended Dec 31, 2008, from $2,169,538 in the prior year, largely due to a reversal of $206,000 in accrued bonuses not expected to be paid. However, for the nine-month period, G&A increased to $6,040,519 from $4,707,419.
- Liquidity: Cash and cash equivalents declined sharply from $6,749,609 at March 31, 2008, to $864,768 at December 31, 2008, reflecting a net cash outflow from operations of $7.2 million for the nine-month period.
- Equity Structure: The company issued redeemable common stock and common stock with registration rights in private placements during the period, resulting in accretion charges of $735,000 (three months) and $2,158,823 (nine months) to fair value, which increased the net loss attributable to common shareholders.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Crisis and Going Concern: Management states that the company's ability to continue as a going concern is dependent on securing additional financing. As of December 31, 2008, cash was approximately $865,000. Proceeds from a February 2009 private placement of $500,000 are estimated to fund operations only through March 31, 2009. Without further capital, operations may cease by the end of February 2009.
- Capital Raising: The company is actively seeking funds through private placements or debt financing. Management has deferred executive salaries, director fees, and approximately $540,000 in accrued legal fees to conserve cash.
- Regulatory Milestones: SpineMedica submitted a 510(k) application for a "vessel guard" product in December 2008, expecting an FDA response in Q1 2009. MiMedx plans to initiate biocompatibility trials in Q2 2009, contingent on securing capital.
- Risk Factors: Significant risks include the inability to raise capital due to the global credit crisis, delays in regulatory approvals, and the potential need to relinquish valuable rights to products or technologies to secure funding.
- Contractual Obligations: Total contractual obligations as of December 31, 2008, were $3,071,000, including $2,018,000 due within one year (consulting, employment, and lease obligations).
Key Facts for Investor Verification
- Cash Runway: Verify the receipt of the $500,000 from the February 2009 private placement and the company's ability to extend operations beyond March 2009.
- Revenue Generation: Confirm the timeline for FDA clearance of the SpineMedica vessel guard and the initiation of clinical trials for MiMedx's core NDGA technology, as the company has no revenue.
- Dilution Risk: Assess the impact of potential future equity issuances required to fund operations, which may significantly dilute existing shareholders.
- Debt and Obligations: Review the $2.0 million in contractual obligations due within one year against the current cash balance of $865,000.
- Accounting Adjustments: Note the significant non-cash charges related to the accretion of redeemable common stock and registration rights, which impacted net loss but did not affect cash flow.